Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease -

Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease
Information type: Randomised controlled trials
Source: New England Journal of Medicine
Specialities: Anaesthesia and pain | Haematological disorders
Summary
Phase 2 RCT (n=198) found that crizalizumab (CZ) therapy (at 5mg/kg, n=67) had a lower rate of sickle-cell related pain crises vs placebo (n=65) over 52 weeks (1.63 vs 2.98, p=0.01). The median time to first crisis was longer for CZ (4.07 vs 1.38 months, p=0.001).
UKMi comment
The rate of sickle-related pain crises per year for the 2.5mg/kg dose was 2.01, which was not statistically different to rate with placebo.
Related links: